Seres Therapeutics, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Seres Therapeutics, Inc. (MCRB) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $50.56 million as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2025-03-13
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $50.56M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $102.56M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $160.59M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2024-12-31 | $50.56M 10-K · filed 2025-03-13 |
| 2023-12-31 | $102.56M 10-K · filed 2025-03-13 |
| 2022-12-31 | $160.59M 8-K · filed 2024-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |